BCDA
Price
$1.53
Change
-$0.17 (-10.00%)
Updated
Sep 17 closing price
Capitalization
9.86M
TGTX
Price
$32.04
Change
+$0.05 (+0.16%)
Updated
Sep 17 closing price
Capitalization
5.08B
42 days until earnings call
Interact to see
Advertisement

BCDA vs TGTX

Header iconBCDA vs TGTX Comparison
Open Charts BCDA vs TGTXBanner chart's image
BioCardia
Price$1.53
Change-$0.17 (-10.00%)
Volume$654.52K
Capitalization9.86M
TG Therapeutics
Price$32.04
Change+$0.05 (+0.16%)
Volume$2.13M
Capitalization5.08B
BCDA vs TGTX Comparison Chart in %
Loading...
BCDA
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
TGTX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
BCDA vs. TGTX commentary
Sep 18, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is BCDA is a Hold and TGTX is a StrongBuy.

Interact to see
Advertisement
COMPARISON
Comparison
Sep 18, 2025
Stock price -- (BCDA: $1.53 vs. TGTX: $32.04)
Brand notoriety: BCDA and TGTX are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: BCDA: 194% vs. TGTX: 91%
Market capitalization -- BCDA: $9.86M vs. TGTX: $5.08B
BCDA [@Biotechnology] is valued at $9.86M. TGTX’s [@Biotechnology] market capitalization is $5.08B. The market cap for tickers in the [@Biotechnology] industry ranges from $100.34B to $0. The average market capitalization across the [@Biotechnology] industry is $1.89B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

BCDA’s FA Score shows that 0 FA rating(s) are green whileTGTX’s FA Score has 1 green FA rating(s).

  • BCDA’s FA Score: 0 green, 5 red.
  • TGTX’s FA Score: 1 green, 4 red.
According to our system of comparison, TGTX is a better buy in the long-term than BCDA.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

BCDA’s TA Score shows that 5 TA indicator(s) are bullish while TGTX’s TA Score has 4 bullish TA indicator(s).

  • BCDA’s TA Score: 5 bullish, 5 bearish.
  • TGTX’s TA Score: 4 bullish, 5 bearish.
According to our system of comparison, BCDA is a better buy in the short-term than TGTX.

Price Growth

BCDA (@Biotechnology) experienced а -27.59% price change this week, while TGTX (@Biotechnology) price change was +0.68% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +1.28%. For the same industry, the average monthly price growth was +6.08%, and the average quarterly price growth was +34.58%.

Reported Earning Dates

TGTX is expected to report earnings on Oct 30, 2025.

Industries' Descriptions

@Biotechnology (+1.28% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
TGTX($5.08B) has a higher market cap than BCDA($9.86M). TGTX YTD gains are higher at: 6.445 vs. BCDA (-29.587). TGTX has higher annual earnings (EBITDA): 97.6M vs. BCDA (-8.81M). TGTX has more cash in the bank: 252M vs. BCDA (980K). BCDA has less debt than TGTX: BCDA (745K) vs TGTX (254M). TGTX has higher revenues than BCDA: TGTX (454M) vs BCDA (0).
BCDATGTXBCDA / TGTX
Capitalization9.86M5.08B0%
EBITDA-8.81M97.6M-9%
Gain YTD-29.5876.445-459%
P/E RatioN/A84.32-
Revenue0454M-
Total Cash980K252M0%
Total Debt745K254M0%
FUNDAMENTALS RATINGS
BCDA vs TGTX: Fundamental Ratings
BCDA
TGTX
OUTLOOK RATING
1..100
223
VALUATION
overvalued / fair valued / undervalued
1..100
88
Overvalued
84
Overvalued
PROFIT vs RISK RATING
1..100
10085
SMR RATING
1..100
10036
PRICE GROWTH RATING
1..100
8954
P/E GROWTH RATING
1..100
1008
SEASONALITY SCORE
1..100
5085

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

TGTX's Valuation (84) in the Biotechnology industry is in the same range as BCDA (88) in the null industry. This means that TGTX’s stock grew similarly to BCDA’s over the last 12 months.

TGTX's Profit vs Risk Rating (85) in the Biotechnology industry is in the same range as BCDA (100) in the null industry. This means that TGTX’s stock grew similarly to BCDA’s over the last 12 months.

TGTX's SMR Rating (36) in the Biotechnology industry is somewhat better than the same rating for BCDA (100) in the null industry. This means that TGTX’s stock grew somewhat faster than BCDA’s over the last 12 months.

TGTX's Price Growth Rating (54) in the Biotechnology industry is somewhat better than the same rating for BCDA (89) in the null industry. This means that TGTX’s stock grew somewhat faster than BCDA’s over the last 12 months.

TGTX's P/E Growth Rating (8) in the Biotechnology industry is significantly better than the same rating for BCDA (100) in the null industry. This means that TGTX’s stock grew significantly faster than BCDA’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
BCDATGTX
RSI
ODDS (%)
Bullish Trend 1 day ago
90%
Bearish Trend 1 day ago
85%
Stochastic
ODDS (%)
Bullish Trend 1 day ago
78%
Bearish Trend 1 day ago
79%
Momentum
ODDS (%)
Bearish Trend 1 day ago
90%
Bullish Trend 1 day ago
79%
MACD
ODDS (%)
Bearish Trend 1 day ago
89%
Bullish Trend 1 day ago
90%
TrendWeek
ODDS (%)
Bearish Trend 1 day ago
90%
Bullish Trend 1 day ago
81%
TrendMonth
ODDS (%)
Bearish Trend 1 day ago
88%
Bullish Trend 1 day ago
81%
Advances
ODDS (%)
Bullish Trend 8 days ago
79%
Bullish Trend 1 day ago
84%
Declines
ODDS (%)
Bearish Trend 1 day ago
89%
Bearish Trend 4 days ago
86%
BollingerBands
ODDS (%)
Bullish Trend 1 day ago
80%
Bearish Trend 1 day ago
77%
Aroon
ODDS (%)
Bullish Trend 1 day ago
74%
Bullish Trend 1 day ago
81%
View a ticker or compare two or three
Interact to see
Advertisement
BCDA
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
TGTX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
IEYCX8.96N/A
N/A
Macquarie Climate Solutions C
OGMCX42.48N/A
N/A
Invesco Gold & Special Minerals C
FBAKX32.60N/A
N/A
Fidelity Balanced K
RPGEX47.92N/A
N/A
T. Rowe Price Global Growth Stock
RTDCX17.22N/A
N/A
Russell Inv Multifactor US Equity C